Safety and radiation-enhancing effect of sodium glycididazole in locoregionally advanced laryngeal cancers previously treated with platinum-containing chemotherapy regimens: A preliminary report

Yue‐Can Zeng, Y. Li(China Medical University), H.B. Zhang(General Hospital of Shenyang Military Region), Xiaozhi Chen(China Medical University), Mei Jia(China Medical University), Harry Hua‐Xiang Xia(Novartis (Switzerland)), W. Chen(China Medical University), Sen Wang(Kunming University of Science and Technology), Ziqi Zhang(China Medical University), Y.M. Wang(China Medical University), X.Y. Zhang(China Medical University), Lingfeng Zhang(General Hospital of Shenyang Military Region), Lin Wu(Materials Systems (United States)), Zhihao Xu(Ministry of Natural Resources), Rong Wu(China Medical University), X. Li(China Medical University), Xue-Mei Jin(China Medical University), Xin-Jun Dong(China Medical University), Enling Wang(China Medical University), Fengping Xiao(China Medical University), Siyu Hao(Harbin Medical University)
Cancer/Radiothérapie
August 20, 2009
10.1016/j.canrad.2009.06.022
Cited by 17

Related Papers

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program
|Blood|2013|677
Aristolochic acid and the etiology of endemic (Balkan) nephropathy
|Proceedings of the National Academy of Sciences|2007|598
Detection and Dynamic Changes of <i>EGFR</i> Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy
|Clinical Cancer Research|2015|469
Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study
|Blood|2012|390
CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study
|Blood|2013|246